Abatacept Manufacturers
Abatacept, commonly known under the trade name Orencia, is a biopharmaceutical used to treat psoriatic arthritis, rheumatoid arthritis, and juvenile idiopathic arthritis. Suppliers of abatacept market it in the form of 250mg lyophilized powder, 125mg prefilled syringes, or 125mg ClickJet prefilled autoinjector pens. The developer and earliest manufacturer of abatacept was Bristol-Meyer Squib who first acquired marketing authorization for it from the FDA in 2005 and the European Medicines Agency in 2007. It has now gained approval in over 50 countries worldwide. Although the patent for Orencia has already expired in the U.S (2019) and in Europe (2017) biosimilar variants of the drug have not been introduced into the market by other manufacturing companies. This can be explained by the high costs and complexity associated with developing biologic medications. Although manufacturers such as BioXpress Therapeutics, Momenta Pharmaceuticals and Mylan are making investments into developing biosimilars, neither has reached the mid or late stages of the process yet. This means that for the time being, the only substitutes for Orencia are different-acting biopharmaceuticals used to treat the same indications.
How Does Abatacept Work?
Similar to CTLA-4, abatacept is a selective costimulation modulator that has been proven to prevent T-cell activation by binding to CD80 and CD86 and preventing CD28 interaction. It has been demonstrated that blocking this connection prevents the second co-stimulatory signal from being delivered, which is necessary for the best activation of T cells. As a result, the activation of autoimmune T-Cells, which has been linked to the aetiology of rheumatoid arthritis, is inhibited. In patients two years of age and older who are receiving hematopoietic stem cell transplant surgery from a matched or 1 allele-mismatched unrelated donor, abatacept is also recommended for the prevention of acute graft-versus-host disease when combined with methotrexate and a calcineurin inhibitor like tacrolimus.
Wholesale Price of Abatacept
The retail price of a single 250mg abatacept vial is approximately 360 EUR. Pharmaceutical specialists are welcome to browse through offers of abatacept lyophilized powders, prefilled syringes, prefilled pens from suppliers on our pharmaceutical marketplace, or else seek out further useful medical information about abatacept online. Abatacept is available for sale from various Abatacept vendors at multiple costs. The price of Abatacept is higher than that of such substitutes, owing largely to the more costly manufacturing process needed to produce it. Also, the costs of Abatacept vary depending on manufacturer and supplier pricing, whether it is a generic or trade name formulation, concentration of the active ingredient in the formulation. It is available or sale at every medical store. Abatacept suppliers, on the whole, are in favor of patient aid initiatives.
From Where to Get Abatacept?
Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified Abatacept manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform. Buyers are advised to buy from PipelinePharma. Making use of Pipelinepharma's worldwide B2B online marketplace for medications and other pharmaceuticals is the ideal approach to locate and acquire access to Abatacept manufacturers and suppliers. Finding reliable suppliers and manufacturers of particular medications like Abatacept can typically be a time-consuming challenge, but with Pipelinepharma's straightforward search engine and network of tested partners, the entire process becomes much simpler. Utilizing our built-in search engine, all you have to do to begin going is start looking for potential Abatacept suppliers or manufacturers. You may also use filters to narrow down your search results and look for Abatacept from particular nations.
Navigating our Pharmaceutical Marketplace
Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Abatacept offerings can be narrowed down with filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for this substance manufacturer and Abatacept suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Abatacept. Also, each manufacturer or supplier product description contains essential information about this substance, including clinical data, stability zones, and countries in which Abatacept is already registered. Manufacturers also have special delivery terms.
Establishing Commercial Ties
Suppose you are a pharmaceutical licensing company or a distributor. In that case, you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the Abatacept suppliers. This way, the marketplace allows you as a distributor to skip the process of making a list of product manufacturers every time you are looking for in-licensing or distribution deals.
Quality Assurance
To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen Abatacept manufacturers for the quality of the pharmaceutical products' dossiers and protect against the risk of possible malpractices.